XML 69 R58.htm IDEA: XBRL DOCUMENT v3.25.2
Segment Information - Sales and Earnings (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Segment Reporting Information [Line Items]        
Net Sales to External Customers $ 11,142 $ 10,377 $ 21,500 $ 20,341
Cost of Products Sold (4,854) (4,603) (9,322) (9,066)
Research and Development (725) (698) (1,441) (1,382)
Selling, General and Administrative (3,091) (2,936) (6,152) (5,895)
Operating Earnings 2,052 1,669 3,745 3,055
Amortization of Intangible assets $ (420) $ (471) $ (840) $ (943)
Restructuring Incurred Cost Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag Other, net (b) Other, net (b) Other, net (b) Other, net (b)
Earnings before Taxes $ 2,150 $ 1,607 $ 3,928 $ 3,043
Annual share-based awards recognized in first quarter (as a percent)     45.00% 45.00%
Operating Segments        
Segment Reporting Information [Line Items]        
Net Sales to External Customers 11,137 10,373 $ 21,492 $ 20,334
Cost of Products Sold (4,768) (4,569) (9,211) (8,976)
Research and Development (681) (638) (1,327) (1,254)
Selling, General and Administrative (2,756) (2,541) (5,362) (5,001)
Operating Earnings 2,932 2,625 5,592 5,103
Operating Segments | Established Pharmaceuticals        
Segment Reporting Information [Line Items]        
Net Sales to External Customers 1,383 1,294 2,643 2,520
Cost of Products Sold (631) (591) (1,200) (1,175)
Research and Development (43) (44) (85) (85)
Selling, General and Administrative (363) (344) (714) (678)
Operating Earnings 346 315 644 582
Operating Segments | Nutritionals        
Segment Reporting Information [Line Items]        
Net Sales to External Customers 2,212 2,150 4,358 4,218
Cost of Products Sold (1,155) (1,148) (2,279) (2,236)
Research and Development (54) (53) (106) (105)
Selling, General and Administrative (585) (576) (1,161) (1,127)
Operating Earnings 418 373 812 750
Operating Segments | Diagnostics        
Segment Reporting Information [Line Items]        
Net Sales to External Customers 2,173 2,195 4,227 4,409
Cost of Products Sold (1,224) (1,203) (2,376) (2,391)
Research and Development (154) (162) (305) (317)
Selling, General and Administrative (423) (400) (815) (797)
Operating Earnings 372 430 731 904
Operating Segments | Medical Devices        
Segment Reporting Information [Line Items]        
Net Sales to External Customers 5,369 4,734 10,264 9,187
Cost of Products Sold (1,758) (1,627) (3,356) (3,174)
Research and Development (430) (379) (831) (747)
Selling, General and Administrative (1,385) (1,221) (2,672) (2,399)
Operating Earnings 1,796 1,507 3,405 2,867
Other        
Segment Reporting Information [Line Items]        
Net Sales to External Customers 5 4 8 7
Reconciling Items        
Segment Reporting Information [Line Items]        
Corporate functions and plan benefit costs (65) (80) (93) (146)
Net interest expense (50) (58) (99) (119)
Share-based compensation (142) (141) (431) (445)
Amortization of Intangible assets (420) (471) (840) (943)
Other, net $ (105) $ (268) $ (201) $ (407)